Market Research Report
In vivo CRO Market Size, Share & Trends Analysis Report By Product Type, By GLP Type, By Indication (Diabetes, Obesity, Autoimmune/Inflammatory, CNS Conditions), And Segment Forecasts, 2019 - 2026
|Published by||Grand View Research, Inc.||Product code||818733|
|Published||Content info||170 Pages
Delivery time: 2-3 business days
|In vivo CRO Market Size, Share & Trends Analysis Report By Product Type, By GLP Type, By Indication (Diabetes, Obesity, Autoimmune/Inflammatory, CNS Conditions), And Segment Forecasts, 2019 - 2026|
|Published: March 27, 2019||Content info: 170 Pages||
The global in vivo cro market is anticipated to reach USD 5.81 billion by 2026, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.5% during the forecast period. Increasing focus on core competencies by the pharmaceutical players coupled with economic efficiency offered for outsourcing is expected to boost the demand.
In Addition, the CROs are equipped with a competent workforce capable of performing a diverse number of tasks along with being well-versed through regulatory requirements. Also, the pressure from the increasing competition owing to rapid growth of generics, patent expirations, and introduction of biosimilar equivalents are encouraging pharmaceutical companies to take the aid of such organizations.
Increasing mergers and collaborations have propelled the value of pharmaceutical outsourcing with major industry contributors expanding into developing regions. The year 2015 experienced high valued transactions as a result of LabCorp acquiring Covance for USD 5.5 billion and the Chinese Private Equity Group acquiring WuXifor USD 3.3 billion. The patent cliff, high research and development cost involved, and globalization in the clinical trial process has driven the
Some of the key market players include: Pharmaceutical Product Development, LLC (PPD); IQVIA; American Preclinical Services, LLC.; Charles River Laboratories; Parexel International Corporation; ICON Plc; Covance Inc.; Theorem Clinical research; inVentiv Health; WuXi AppTec, Inc.; American Preclinical Services, LLC.; and Evotec (US), Inc. Partnership and mergers and acquisitions are the key strategic undertakings by these players